PR1 peptide vaccine

PR1 peptide vaccine is an investigational immunotherapy consisting of a 9-amino acid peptide (VLQELNVTV) derived from the leukemia-associated antigens proteinase 3 (P3) and neutrophil elastase (NE). These antigens are overexpressed in the primary granules of myeloid leukemia cells, particularly in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The vaccine is designed to elicit a specific cytotoxic T-lymphocyte (CTL) response against HLA-A2+ myeloid leukemia cells by stimulating the expansion of PR1-specific T cells that recognize and lyse malignant cells. In clinical development, the vaccine is typically administered in combination with an adjuvant, such as sargramostim (GM-CSF), to enhance its immunogenicity. The development was primarily driven by The Vaccine Company, focusing on maintaining remission and preventing relapse in patients with AML.

Other names

PR1 leukemia peptide vaccinePR-1 leukemia peptide vaccinePR 1 leukemia peptide vaccinePR1 peptidePR-1 peptidePR 1 peptidePR1 leukemia vaccinePR-1 leukemia vaccinePR 1 leukemia vaccine